Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece

BMC Dermatology

Volumn 12, Issue , 2012, Pages

  Avgerinou, Georgia ^c   Bassukas, Ioannis ^a   Chaidemenos, Georgios ^b   Katsampas, Andreas ^c   Kosmadaki, Marita ^c   Kousoulakou, Hara ^h   Petridis, Athanasios ^a   Schenkel, Brad ⁱ   Sotiriadis, Dimitrios ^d   Spiliopoulos, Theofanis ^e   Stavropoulos, Panagiotis ^c   Toumpi, Evgenia ^f   Xaplanteris, Loukas ^g  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Hospital for Skin and Venereal Diseases   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

^f NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^g Janssen Cilag Pharmaceutical SACI   (Greece)

^h PRMA Consulting Ltd   (United Kingdom)

ⁱ Janssen Scientific Affairs LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB; BIOLOGICAL FACTOR; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ARTICLE; BUDGET; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DERMATOLOGIST; DISEASE SEVERITY; DRUG ADMINISTRATION; DRUG EFFICACY; DRUG MONITORING; GREECE; HEALTH CARE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INTERVIEW; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS SEVERITY INDEX; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; FEMALE; HEALTH CARE COST; MALE; QUESTIONNAIRE; STATISTICAL MODEL;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL FACTORS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GREECE; HEALTH CARE COSTS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MODELS, ECONOMIC; PSORIASIS; QUESTIONNAIRES;

EID: 84865292969     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-12-10     Document Type: Article

References (37)

1. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006, 10:No 46.
2. Lebwohl M. Psoriasis. Lancet 2003, 361:1197-1204. 10.1016/S0140-6736(03)12954-6, 12686053.
3. Kyriakis KP, Palamaras I, Pagana G, Terzoudi S, Evangelou G. Lifetime prevalence fluctuations of chronic plaque psoriasis and other non-pustular clinical variants. J Eur Acad Dermatol Venereol 2008, 22:1513-1514. 10.1111/j.1468-3083.2008.02692.x, 18482310.
4. Stern RS. Psoriasis. Lancet 1997, 350:349-353. 10.1016/S0140-6736(97)05257-4, 9251649.
5. National Psoriasis Foundation The psoriasis and psoriatic arthritis pocket guide -Treatment algorithms and management options 2009, , Portland, National Psoriasis Foundation.
6. Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani P. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009, 25:2429-2438. 10.1185/03007990903185557, 19663687.
7. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999, 41:401-407. 10.1016/S0190-9622(99)70112-X, 10459113.
8. Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, Sexton SA, et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc 2004, 9:160-168. 10.1046/j.1087-0024.2003.09112.x, 15083784.
9. Zug KA, Littenberg B, Baughman RD, Kneeland T, Nease RF, Sumner W, et al. Assessing the preferences of patients with psoriasis. A quantitative, utility approach. Arch Dermatol 1995, 131:561-568. 10.1001/archderm.1995.01690170063009, 7741543.
10. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007, 215:17-27. 10.1159/000102029, 17587835.
11. Fried RG, Friedman S, Paradis C, Hatch M, Lynfield Y, Duncanson C, et al. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995, 34:101-105. 10.1111/j.1365-4362.1995.tb03588.x, 7737765.
12. Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 2002, 16:347-352. 10.1046/j.1468-3083.2002.00467.x, 12224690.
13. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int J Dermatol 1993, 32:188-190. 10.1111/j.1365-4362.1993.tb02790.x, 8444530.
14. Bhosle MJ, Feldman SR, Camacho FT, Timothy WJ, Nahata MC, Balkrishnan R. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat 2006, 17:294-301. 10.1080/09546630600954594, 17092860.
15. Cockayne SE, Cork MJ, Gawkrodger DJ. Treatment of psoriasis: day care vs. inpatient therapy. Br J Dermatol 1999, 140:375-376. 10.1046/j.1365-2133.1999.02691.x, 10233251.
16. Colombo G, Altomare G, Peris K, Martini P, Quarta G, Congedo M, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008, 4:559-568. 2504078, 18728854.
17. Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm 2004, 10:318-325.
18. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003, 206:307-315. 10.1159/000069942, 12771471.
19. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004, 150:317-326. 10.1111/j.1365-2133.2004.05697.x, 14996104.
20. Farhi D, Dupin N. Biologic therapies in the treatment of psoriasis. Presse Med 2009, 38:832-843. 10.1016/j.lpm.2008.07.023, 19282134.
21. Bongartz R, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285. 10.1001/jama.295.19.2275, 16705109.
22. Bissonnette R, Ho V, Langley RG. Safety of Conventional Systemic Agents and Biologic Agents in the treatment of Psoriasis. J Cutan Med Surg 2009, 13(2):S67-S76.
23. Chien AL, Elder JT, Ellis CN. Ustekinumab: a new option in psoriasis therapy. Drugs 2009, 69:1141-1152. 10.2165/00003495-200969090-00001, 19537833.
24. Weber J, Keam SJ. Ustekinumab. BioDrugs 2009, 23:53-61. 10.2165/00063030-200923010-00006, 19344192.
25. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674. 10.1016/S0140-6736(08)60725-4, 18486739.
26. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684. 10.1016/S0140-6736(08)60726-6, 18486740.
27. Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis. Br J Dermatol 2012, 166:179-188. 10.1111/j.1365-2133.2011.10583.x, 21910698.
28. Griffiths C, Strober BE, Van de Kerkhof P, Ho V, Fidelus-Gort H, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010, 362:118-128. 10.1056/NEJMoa0810652, 20071701.
29. Chu E, Cartwright TH. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer. J Clin Oncol 2008, 26:2224-2226. 10.1200/JCO.2008.16.2826, 18445854.
30. Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health 2008, 18:275-282. 10.1093/eurpub/ckm123, 18160389.
31. ISPOR Drug Cost Task Force Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses 2010, , South Lawrenceville, ISPOR Drug Cost Task Force.
32. Feldman SR, Fleischer AB, Reboussin DM, Rapp SR, Bradham DD, Exum ML, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997, 37:564-569. 10.1016/S0190-9622(97)70172-5, 9344194.
33. Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010, 162:137-146. 10.1111/j.1365-2133.2009.09491.x, 19903183.
34. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu M-C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled Phase III trial. J Am Acad Dermatol 2010, 63:457-465. 10.1016/j.jaad.2009.09.014, 20462664.
35. Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Borcier M, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Derm Treat 2011, 22:337-347.
36. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995, 132:236-244.
37. Schoffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 2007, 5:209-218. 10.1111/j.1610-0387.2007.06240.x, 17338796.